Related references
Note: Only part of the references are listed.Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases
Eun Jung Choi et al.
BMC CANCER (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2014)
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
Peiwen Yu et al.
MOLECULAR CANCER THERAPEUTICS (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Current clinical development of PI3K pathway inhibitors in glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2012)
NORTH CENTRAL CANCER TREATMENT GROUP PHASE I TRIAL N057K OF EVEROLIMUS (RAD001) AND TEMOZOLOMIDE IN COMBINATION WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Jann N. Sarkaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Status of PI3K inhibition and biomarker development in cancer therapeutics
B. Markman et al.
ANNALS OF ONCOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Neil A. O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Ben Markman et al.
ONCOTARGET (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase
Marcella Priulla et al.
PROSTATE (2007)
Phosphatase and tensin homologue deficiency in giloblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir
Zibin Jiang et al.
CANCER RESEARCH (2007)
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors
Ingo K. Mellinghoff et al.
CLINICAL CANCER RESEARCH (2007)
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme
Gary L. Gallia et al.
MOLECULAR CANCER RESEARCH (2006)
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo
H Momota et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
